Multivariable model predicting SMM risk for PD
| n = 90* . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age | 1.002 (0.97-1.03) | .9007 | ||
| Male | 0.88 (0.47-1.65) | .6824 | ||
| BMPC ≥20% | 3.29 (1.45-7.49) | .0046 | ||
| BMPC ≥60% | 0.98 (0.30-3.25) | .9790 | ||
| m-protein ≥3 g/dL | 3.59 (1.80-7.17) | .0003 | ||
| IgA SMM | 0.72 (0.30-1.73) | .4645 | ||
| Immunoparesis | 2.90 (1.46-5.77) | .0025 | 3.90 (1.80-8.44) | .0006 |
| FLCr ≥100 and dFLC ≥100 | 1.53 (0.59-3.99) | .3827 | ||
| dFLC ≥100 mg/L | 1.36 (0.70-2.64) | .3658 | ||
| eMP | 3.64 (1.89-6.99) | .0001 | 3.98 (1.80-8.44) | <.0001 |
| eHb | 4.54 (2.22-9.29) | <.0001 | 8.05 (3.53-18.35) | <.0001 |
| eFLCr | 2.09 (1.04-4.21) | .0395 | ||
| edFLC | 3.02 (1.45-6.27) | .0031 | 2.84 (1.28-6.29) | .0100 |
| n = 90* . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Age | 1.002 (0.97-1.03) | .9007 | ||
| Male | 0.88 (0.47-1.65) | .6824 | ||
| BMPC ≥20% | 3.29 (1.45-7.49) | .0046 | ||
| BMPC ≥60% | 0.98 (0.30-3.25) | .9790 | ||
| m-protein ≥3 g/dL | 3.59 (1.80-7.17) | .0003 | ||
| IgA SMM | 0.72 (0.30-1.73) | .4645 | ||
| Immunoparesis | 2.90 (1.46-5.77) | .0025 | 3.90 (1.80-8.44) | .0006 |
| FLCr ≥100 and dFLC ≥100 | 1.53 (0.59-3.99) | .3827 | ||
| dFLC ≥100 mg/L | 1.36 (0.70-2.64) | .3658 | ||
| eMP | 3.64 (1.89-6.99) | .0001 | 3.98 (1.80-8.44) | <.0001 |
| eHb | 4.54 (2.22-9.29) | <.0001 | 8.05 (3.53-18.35) | <.0001 |
| eFLCr | 2.09 (1.04-4.21) | .0395 | ||
| edFLC | 3.02 (1.45-6.27) | .0031 | 2.84 (1.28-6.29) | .0100 |
Only 6 patients had BMPC ≥60%, thereby limiting detection of statistical differences in progression curves at this cutoff.
HR, hazard ratio.
Patients were required to have all listed variables to be eligible for complete case analysis.